Top

Published in:

Open Access 01-07-2015 | Original Article

Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000–2010

Authors: C. Klop, D. Gibson-Smith, P. J. M. Elders, P. M. J. Welsing, H. G. M. Leufkens, N. C. Harvey, J. W. J. Bijlsma, T.-P. van Staa, F. de Vries

Published in: Osteoporosis International | Issue 7/2015

Abstract

Summary

The probability of initiating with anti-osteoporosis therapy increased from 7 % in 2000 to 46 % in 2010. This improvement was greater for patients over the age of 75 years. Men, those overweight, having dementia or exposed to antipsychotics, sedatives/hypnotics or opioid analgesics were significantly less likely to receive anti-osteoporosis drugs.

Introduction

The objective of this study was to examine trends and determinants of anti-osteoporosis drug prescribing after hip fracture in the UK between 2000 and 2010.

Methods

Data were extracted from the UK Clinical Practice Research Datalink for patients ≥50 years who had a first hip fracture between 2000 and 2010 and who did not currently (≤6 months prior) receive anti-osteoporosis drugs (bisphosphonates, strontium ranelate, parathyroid hormone, calcitonin and raloxifene) (n = 27,542). The cumulative incidence probability of being prescribed anti-osteoporosis drugs within 1 year after hip fracture was estimated by Kaplan-Meier life-table analyses. Determinants for treatment initiation were estimated by Cox proportional hazards models.

Results

The probability of being prescribed any anti-osteoporosis drug after hip fracture increased from 7 % in 2000 to 46 % in 2010. This trend was more marked in patients ≥75 years. The increase in prescribing of anti-osteoporosis drugs was complemented by a similar increase in vitamin D/calcium provision. Cumulative incidence of receiving anti-osteoporosis therapy was greater at any given point in time in women (8 % in 2000, 51 % in 2010) compared to men (4 % in 2000, 34 % in 2010). In addition to male gender, multivariable Cox regression identified reduced likelihood of receiving anti-osteoporosis drugs for those being overweight, having dementia and exposed to psychotropic drugs (antipsychotics, sedatives/hypnotics) or opioid analgesics.

Conclusion

Although the prescribing of anti-osteoporosis drugs after hip fracture has increased substantially since 2000, the overall rate remained inadequate, particularly in men. With the continuing increase in the absolute number of hip fractures, further research should be made into the barriers to optimise osteoporosis management.

National osteoporosis society, URL: http://www.nos.org.uk/page.aspx?pid=328 Accessed 22 January 2015

Smith P, Ariti C, Bardsley M (2013) Focus on hip fracture: trends in emergency admission for fractured neck of femur, 2001 to 2011. Nuffield Trust/Health Foundation, London

Warriner AH, Patkar NM, Yun H, Delzell E (2012) Minor, major, low-trauma, and high-trauma fractures: what are the subsequent fracture risks and how do they vary? Curr Osteoporos Rep 10:22–27CrossRef

von Friesendorff M, Besjakov J, Akesson K (2008) Long-term survival and fracture risk after hip fracture: a 22-year follow-up in women. J Bone Miner Res 23:1832–1841CrossRef

van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ (2009) Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 68:99–102PubMedCrossRef

Medicines and Healthcare products Regulatory Agency (MHRA)/Committee on Safety of Medicines (2004) Review of the evidence on long-term safety of HRT. Curr Probl Phamacovigilance 30:4–6

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRef

Reginster JY (2011) Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 71:65–78PubMedCrossRef

Formiga F, Rivera A, Nolla JM, Coscujuela A, Sole A, Pujol R (2005) Failure to treat osteoporosis and the risk of subsequent fractures in elderly patients with previous hip fracture: a five year retrospective study. Aging Clin Exp Res 17:96–99PubMedCrossRef

10.

Rabenda V, Vanoverloop J, Fabri V, Mertens R, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY (2008) Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am 90:2142–2148PubMedCrossRef

11.

Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD (2006) Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum 35:293–305PubMedCrossRef

12.

Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 29:1929–1937PubMedCentralPubMedCrossRef

13.

McGowen B, Bennet K, Casey MC, Doherty J, Silke C, Whelan B (2013) Comparison of prescribing and adherence patterns of anti-osteoporotic medications post-admission for fragility type fracture in an urban teaching hospital and a rural teaching hospital in Ireland between 2005–2008. Ir J Med Sci 182:601–608CrossRef

14.

Fisher A, Martin J, Srikusalanukul W, Davis M (2010) Bisphosphonate use and hip fracture epidemiology: ecological proof from the contrary. Clin Interv Aging 5:355–362PubMedCentralPubMedCrossRef

15.

Fraser LA, Ioannidis G, Adachi JD, Pickard L, Kaiser SM, Pior J et al (2011) Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study. Osteoporos Int 22:789–796PubMedCrossRef

16.

Cadarette SM, Katz JN, Brookhart MA, Levin R, Stedman MR, Choudhry NK, Solomon DH (2008) Trends in drug prescribing for osteoporosis after hip fracture, 1995–2004. J Rheumatol 35:319–326PubMedCentralPubMed

17.

Roerholt C, Eikken P, Abrahamsen B (2009) Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int 20:299–307PubMedCrossRef

18.

Brauer CA, Coa-Perraillon M, Cutler DM, Rosen AB (2009) Incidence and mortality of hip fractures in the United States. JAMA 302:1573–1579PubMedCentralPubMedCrossRef

19.

Alves SM, Economou T, Oliveira C, Ribeiro NN, Gomez-Barrena PMF (2012) Osteoporotic hip fractures: bisphosphonates sales and observed turning point in trend. A population-based retrospective study. Bone 53:430–436PubMedCrossRef

20.

Watson J, Wise L, Green J (2007) Prescribing of hormone replacement therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005 Eur J. Clin Pharmacol 63:843–849CrossRef

21.

Reymondier A, Caillet P, Abbas-Chorfa F, Ambrosi V, Jaglal SB, Chapurlat R et al (2013) MENOPOST—calcium and vitamin D supplementation in post-menopausal osteoporosis treatment: a descriptive cohort study. Osteoporos Int 24:559–566PubMedCrossRef

22.

Hanley DA, Zhang Q, Meilleur MC, Mavros P, Sen SS (2007) Prescriptions for vitamin D among patients taking antiresorptive agents in Canada. Curr Med Res Opin 23:1473–1480PubMedCrossRef

23.

Bayly JR, Hollands RD, Riordan-Jones SE, Yemm SJ, Brough-Williams I, Thatcher M et al (2006) Prescribed vitamin D and calcium preparations in patients treated with bone remodeling agents in primary care: a report of a pilot study. Curr Med Res Opin 22:131–137PubMedCrossRef

24.

Royal College of Physicians. Falling standards, broken promises. Report of the national audit of falls and bone health in older people 2010. URL: https://www.rcplondon.ac.uk/sites/default/files/national_report.pdf, assessed 25 Jan 2015

25.

Balasubramanian A, Brookhart MA, Goli V, Critchlow CW (2013) Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women. Int J Gen Med 6:839–848PubMedCentralPubMedCrossRef

26.

National Institute for Health and Care Excellence (2008) Technological appraisal (TA)161 Osteoporosis-Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

27.

Kanis JA, Mc Closkey EV, Johansson H, Oden A, Ström O, Borgström F (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21:407–413CrossRef

28.

National Institute for Health and Care Excellence (2005) Technology appraisal (TA)87. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

29.

Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195–202PubMedCrossRef

30.

Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS et al (2003) BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 18:1947–1954PubMedCrossRef

31.

Wang L, Shawn Tracy C, Moineddin R, Upshur RE (2013) Osteoporosis prescribing trends in primary care: a population-based retrospective cohort study. Prim Health Care Res Dev 14:1–6PubMedCrossRef

32.

Peeters G, Tett SE, Duncan EL, Mishra GD, Dobson AJ (2014) Osteoporosis medication dispensing for older Australian women from 2002 to 2010: influences of publications, guidelines, marketing activities and policy. Pharmacoepidemiol Drug Saf 23:1303–1311PubMedCrossRef

33.

McLellan AR, Gallacher SJ, Fraser M, McQuillian C (2003) The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int 14:1028–1034PubMedCrossRef

34.

Zhang J, Delzell E, Curtis JR, Hooven F, Gehlbach SH, Anderson FA, Saag KG (2013) Use of pharmacologic agents for the primary prevention of osteoporosis among older women with low bone mass. Osteoporos Int 25:317–324PubMedCrossRef

35.

Bessette L, Jean S, Davison KS, Roy S, Ste-Marie LG, Brown JP (2009) Factors influencing the treatment of osteoporosis following fragility fracture. Osteoporos Int 20:1911–1919PubMedCrossRef

36.

Wilk A, Sajjan S, Modi A, Fan C-PS, Mavros P (2014) Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA. Osteoporos Int 25:2777–2786PubMedCentralPubMedCrossRef

37.

Ettinger B, Chidambaran P, Pressman A (2001) Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. Am J Manage care 7:597–605

38.

Beaton DE, Dyer S, Jiang D, Sujic R, Slater M, Sale JEM, Bogoch ER (2014) Factors influencing the pharmacological management of osteoporosis after fragility fracture: results from the Ontario Osteoporosis Strategy’s fracture clinic screening program. Osteoporos Int 25:289–296PubMedCrossRef

39.

Duyvendak M, Naunton M, van Roon EN, Brouwers JRBJ (2011) Doctors’ beliefs and knowledge on corticosteroid-induced osteoporosis: identifying barriers to improve prevention. J Clin Pharm Ther 36:356–366PubMedCrossRef

40.

Asche C, Nelson R, McAdam-Marx C, Jhaveri M, Ye X (2010) Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA. Osteoporos Int 21:1427–1436PubMedCentralPubMedCrossRef

41.

Nayak S, Roberts MS, Chang CC, Greenspan SL (2010) Health beliefs about osteoporosis and osteoporosis screening in older women and men. Health Educ J 69:267–276PubMedCentralPubMedCrossRef

42.

Jaglal SB, Carrol J, Hawker G et al (2003) How are family physicians managing osteoporosis? Qualitative study of their experiences and educational needs. Can Fam Physician 49:462–468PubMedCentralPubMed

43.

Johnson CS, McLeod W, Kennedy L, McLeod K (2008) Osteoporosis health beliefs among younger and older men and women. Health Educ Behave 35:721–733CrossRef

44.

Sedlak CA, Doheny MO, Estok PJ (2000) Osteoporosis in older men: knowledge and health beliefs. Orthop Nurs 19:38–42PubMedCrossRef

45.

Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Adami J, Graham S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610PubMedCrossRef

46.

Lyles K, Colon-Emeric C, Magaziner J, Adachi J, Pieper C, Mautalen C et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRef

47.

Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493–1501PubMedCrossRef

48.

Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397PubMedCentralPubMedCrossRef

49.

Compston J, Bowring C, Cooper A, Cooper C, Davies C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P; National Osteoporosis Guideline Group (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update. Maturitas 75:392–6

50.

Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr, McLellan A, Mitchell PJ, Silverman S, Singleton R, Siris E (2012) ASBMR Task Force on Secondary Fracture Prevention. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res 27:2039–2046PubMedCrossRef

51.

Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, Kyer C, Cooper C, IOF Fracture Working Group (2013) Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int 24:2135–2152PubMedCentralPubMedCrossRef

Title: Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000–2010
Authors: C. Klop
D. Gibson-Smith
P. J. M. Elders
P. M. J. Welsing
H. G. M. Leufkens
N. C. Harvey
J. W. J. Bijlsma
T.-P. van Staa
F. de Vries
Publication date: 01-07-2015
Publisher: Springer London
Published in: Osteoporosis International / Issue 7/2015
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-015-3098-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000–2010

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2015

Memories of Stephen Hough (27.08.1947–05.12.2014)

Inadequate management for secondary fracture prevention in patients with distal radius fracture by trauma surgeons

Erratum to: Clinician’s guide to prevention and treatment of osteoporosis

Ischemic heart disease is associated with lower cortical volumetric bone mineral density of distal radius

Excess mortality associated with second hip fracture

District nurses’ perceptions of osteoporosis management: a qualitative study